Home › Compare › ORENF vs ABBV
ORENF yields 3.81% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ORENF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ORENF + ABBV for your $10,000?
Origin Enterprises plc provides agronomy services company in Ireland, the United Kingdom, Belgium, Brazil, Poland, Romania, Ukraine, and Latin America. It develops products and services to improve soil fertility, nutrient use efficiency, and crop productivity. The company provides integrated agronomy and on-farm services comprising agronomy advice, services, and inputs directly to arable, fruit, and vegetable growers; and seed, nutrients, crop protection products and digital tools. It also offers procurement and supply chain solutions comprising prescription blended fertilizers and animal feed ingredients; and digital agronomy applications and agri-tech services to primary producers, input manufacturers, and agri-service companies. In addition, the company engages in the provision of advisory, service, and input, as well as turf and amenity management solutions to the professional sports turf, landscaping, and amenity sectors. Further, it is involved in the manufacture and distribution of landscaping, forestry, and maintenance equipment; IT implementation, maintaining, and licensing of software; grain handling; grain and feed trading; property trading; provender milling; and silo operation business. Additionally, the company provides sports and amenities; and agricultural and construction inputs. It provides its solutions under the Agrii, Goulding, Fortgreen, RHIZA, Origin Amenity Solutions, Origin Fertilisers, PB Kent, Linemark, Green-tech, and Origin Digital brand names. Origin Enterprises plc was incorporated in 2006 and is based in Dublin, Ireland.
Full ORENF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.